

**EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO®) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.

Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).

“DAYVIGO continues to serve as an important asset to Eisai’s neurology portfolio and we look forward to presenting the findings from several analyses at this year’s SLEEP Meeting,” said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. “Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,<sup>1, 2</sup> and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs.”

**SLEEP 2022 Presentations**

<b>Asset in Product, Session, Time (Eastern Time)</b>	<b>Title, Author, Presenter</b>
<b>Lemborexant</b> Poster presentation Poster #168 Monday, June 6, 6:15 PM – 7:15 PM Oral presentation session: O-31 Wednesday, June 8, 3:15 PM	Subjective Sleep Outcomes with Lemborexant Among Subjects with Insomnia and Clinically Meaningful Decreases on the Insomnia Severity Index Authors: Dr. Thomas Roth, et al Presenter: Dr. Margaret Moline
<b>Lemborexant</b> Poster presentation Poster #169 Monday, June 6, 5:15 PM – 6:15 PM	Correlations Between Sleep Parameters and ISI Total Score in Subjects with Moderate to Severe Insomnia Treated with Lemborexant Authors: Dr. Margaret Moline, et al
<b>Lemborexant</b> Poster presentation Poster #170 Monday, June 6, 6:15 PM – 7:15 PM	Effect of Lemborexant on Early Morning Awakening in Subjects with Severe Problems with Waking Too Early Authors: Dr. Margaret Moline, et al
<b>Lemborexant</b> Poster presentation Poster #171 Monday, June 6, 5:15 PM – 6:15 PM Oral presentation session: O-31 Wednesday, June 8, 4:45 PM	Effect of Lemborexant Treatment on Polysomnographic Sleep Measures in Older Adults with Insomnia and Objective Short Sleep Authors: Dr. Andrew D. Krystal, et al Presenter: Dr. Margaret Moline

<b>Lemborexant</b> Poster presentation Poster #172 Monday, June 6, 6:15 PM – 7:15 PM Oral presentation session: O-31 Wednesday, June 8, 5:00 PM	Lemborexant Treatment of Older Adults with Insomnia and Objective Short Sleep: Rates of Response and Remission  Authors: Dr. Jack D. Edinger, et al  Presenter: Dr. Jack D. Edinger
<b>Lemborexant</b> Poster presentation Poster #173 Monday, June 6, 5:15 PM – 6:15 PM	Lemborexant Exposure is Independent of Race  Authors: Dr. Sumit Rawal, et al
<b>Lemborexant</b> Poster presentation Poster #174 Monday, June 6, 6:15 PM – 7:15 PM	Response to Lemborexant in Older Subjects with Insomnia Disorder and Comorbid Pain at Baseline  Authors: Dr. Alan Kaplan, et al

Please note, the poster presentation time is 5:15 PM – 7:15 PM on Monday, June 6 with odd numbered poster presentations taking place from 5:15 PM – 6:15 PM and even numbered poster presentations from 6:15 PM – 7:15 PM.

Media Inquiries	Investor Contact
Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120  Eisai Inc. (U.S.) TEL: +551-305-0050 Christopher_Vancheri@eisai.com	Eisai Co., Ltd. Investor Relations Department TEL: +81-(0)70-8688-9685

**[Notes to editors]**

**1. About Lemborexant (product name: DAYVIGO®)**

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.

<sup>1</sup> Ferrie JE, et al. Sleep epidemiology – a rapidly growing field. *Int J Epidemiol.* 2011;40(6):1431–1437.

<sup>2</sup> Roth T. Insomnia: definition, prevalence, etiology and consequences. *J Clin Sleep Med.* 2007;3(5 Suppl):S7–S10